Thermo Fisher Scientific Inc. $TMO Shares Purchased by United Asset Strategies Inc.

Key Points

• United Asset Strategies Inc. has increased its stake in Thermo Fisher Scientific Inc. by 33.3%, now holding 36,339 shares valued at approximately $18.1 million.
• Thermo Fisher reported a quarterly EPS of $5.36, exceeding analysts' expectations, with revenue reaching $10.86 billion and a year-over-year increase of 2.9%.
• The company declared a quarterly dividend of $0.43, providing an annual yield of 0.3%, with the ex-dividend date set for September 15th.

United Asset Strategies Inc. grew its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 33.3% during the 1st quarter, according to the company in its most recent disclosure with the SEC. The fund owned 36,339 shares of the medical research company's stock after purchasing an additional 9,070 shares during the quarter. Thermo Fisher Scientific comprises 1.7% of United Asset Strategies Inc.'s portfolio, making the stock its 10th biggest holding. United Asset Strategies Inc.'s holdings in Thermo Fisher Scientific were worth $18,082,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Bernard Wealth Management Corp. acquired a new stake in shares of Thermo Fisher Scientific in the fourth quarter valued at about $25,000. Ameriflex Group Inc. bought a new stake in shares of Thermo Fisher Scientific in the fourth quarter valued at about $30,000. Keystone Global Partners LLC bought a new stake in shares of Thermo Fisher Scientific in the first quarter valued at about $31,000. IMA Advisory Services Inc. bought a new stake in shares of Thermo Fisher Scientific in the first quarter valued at about $35,000. Finally, Navigoe LLC bought a new stake in shares of Thermo Fisher Scientific in the fourth quarter valued at about $37,000. 89.23% of the stock is owned by institutional investors and hedge funds.

Thermo Fisher Scientific Price Performance

Shares of NYSE:TMO traded up $16.4780 during trading on Friday, reaching $500.2380. The stock had a trading volume of 1,778,365 shares, compared to its average volume of 2,406,376. Thermo Fisher Scientific Inc. has a 52 week low of $385.46 and a 52 week high of $627.88. The business's 50-day moving average price is $443.02 and its 200 day moving average price is $456.60. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.93 and a quick ratio of 1.50. The stock has a market capitalization of $188.89 billion, a PE ratio of 28.93, a P/E/G ratio of 2.67 and a beta of 0.74.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last posted its earnings results on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $5.22 by $0.14. The company had revenue of $10.86 billion during the quarter, compared to analysts' expectations of $10.68 billion. Thermo Fisher Scientific had a net margin of 15.24% and a return on equity of 16.82%. Thermo Fisher Scientific's quarterly revenue was up 2.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $5.37 earnings per share. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. As a group, equities analysts predict that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current year.

Thermo Fisher Scientific Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, October 15th. Investors of record on Monday, September 15th will be issued a $0.43 dividend. The ex-dividend date of this dividend is Monday, September 15th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 0.3%. Thermo Fisher Scientific's dividend payout ratio (DPR) is currently 9.95%.

Insider Buying and Selling

In related news, EVP Gianluca Pettiti sold 400 shares of the firm's stock in a transaction that occurred on Friday, July 25th. The shares were sold at an average price of $479.98, for a total value of $191,992.00. Following the completion of the sale, the executive vice president owned 22,367 shares of the company's stock, valued at $10,735,712.66. This trade represents a 1.76% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO Marc N. Casper sold 295 shares of the firm's stock in a transaction that occurred on Wednesday, August 20th. The shares were sold at an average price of $500.04, for a total transaction of $147,511.80. Following the completion of the sale, the chief executive officer directly owned 115,174 shares of the company's stock, valued at approximately $57,591,606.96. This represents a 0.26% decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 18,896 shares of company stock valued at $8,593,838. 0.33% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

TMO has been the subject of several research reports. Hsbc Global Res cut shares of Thermo Fisher Scientific from a "strong-buy" rating to a "hold" rating in a research note on Thursday, July 24th. Raymond James Financial reiterated an "outperform" rating and issued a $535.00 target price (up previously from $525.00) on shares of Thermo Fisher Scientific in a research note on Thursday, July 24th. Wells Fargo & Company cut their price target on shares of Thermo Fisher Scientific from $570.00 to $565.00 and set an "overweight" rating for the company in a research note on Thursday, July 24th. Barclays raised their price target on shares of Thermo Fisher Scientific from $450.00 to $490.00 and gave the stock an "equal weight" rating in a research note on Thursday, July 24th. Finally, Argus cut their price target on shares of Thermo Fisher Scientific from $620.00 to $470.00 and set a "buy" rating for the company in a research note on Tuesday, April 29th. Sixteen analysts have rated the stock with a Buy rating and six have given a Hold rating to the stock. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $593.00.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.